HLS Therapeutics Inc. (FRA:74D)
Germany
· Delayed Price · Currency is EUR 2.900
+0.060 (2.11%)
At close: Dec 4, 2025
HLS Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 55.85 | 56.62 | 63.07 | 61.47 | 60.01 | 56.11 | Upgrade
|
| Revenue Growth (YoY) | -1.92% | -10.23% | 2.61% | 2.43% | 6.95% | 3.60% | Upgrade
|
| Cost of Revenue | 15.74 | 14.66 | 13.2 | 10.71 | 9.65 | 9.09 | Upgrade
|
| Gross Profit | 40.11 | 41.96 | 49.88 | 50.76 | 50.36 | 47.02 | Upgrade
|
| Selling, General & Admin | 20.64 | 25.31 | 28.82 | 26.93 | 24.02 | 23.39 | Upgrade
|
| Operating Expenses | 44.75 | 49.65 | 60.23 | 64.26 | 56.64 | 59.1 | Upgrade
|
| Operating Income | -4.64 | -7.69 | -10.35 | -13.5 | -6.28 | -12.09 | Upgrade
|
| Interest Expense | -8.5 | -10.08 | -8.75 | -7.32 | -6.96 | -6.31 | Upgrade
|
| Interest & Investment Income | 0.13 | 0.32 | 0.35 | 0.06 | 0.04 | 0.32 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.39 | -0 | 0.05 | -0.11 | -0.41 | -0.27 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.21 | -0.99 | -1.73 | 1.54 | 1.8 | 2.75 | Upgrade
|
| EBT Excluding Unusual Items | -13.83 | -18.44 | -20.43 | -19.33 | -11.81 | -15.59 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | - | -0.71 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 3.38 | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | -3.89 | -3.05 | - | - | Upgrade
|
| Other Unusual Items | -0.52 | -0.52 | -3.48 | -1.34 | - | - | Upgrade
|
| Pretax Income | -13.83 | -15.58 | -27.8 | -23.72 | -11.81 | -16.3 | Upgrade
|
| Income Tax Expense | 0.29 | 4.07 | -0.27 | -0.12 | 1.31 | -0.97 | Upgrade
|
| Net Income | -14.12 | -19.66 | -27.53 | -23.6 | -13.12 | -15.33 | Upgrade
|
| Net Income to Common | -14.12 | -19.66 | -27.53 | -23.6 | -13.12 | -15.33 | Upgrade
|
| Shares Outstanding (Basic) | 32 | 32 | 32 | 32 | 32 | 32 | Upgrade
|
| Shares Outstanding (Diluted) | 32 | 32 | 32 | 32 | 32 | 32 | Upgrade
|
| Shares Change (YoY) | -0.81% | -1.31% | -0.52% | 0.77% | 1.48% | 8.01% | Upgrade
|
| EPS (Basic) | -0.45 | -0.62 | -0.85 | -0.73 | -0.41 | -0.48 | Upgrade
|
| EPS (Diluted) | -0.45 | -0.62 | -0.85 | -0.73 | -0.41 | -0.48 | Upgrade
|
| Free Cash Flow | 13.64 | 7.99 | 15.75 | 16.9 | 16.38 | 9.31 | Upgrade
|
| Free Cash Flow Per Share | 0.43 | 0.25 | 0.49 | 0.52 | 0.51 | 0.29 | Upgrade
|
| Dividend Per Share | - | - | 0.076 | 0.148 | 0.158 | 0.157 | Upgrade
|
| Dividend Growth | - | - | -48.76% | -6.50% | 0.69% | 1.79% | Upgrade
|
| Gross Margin | 71.82% | 74.11% | 79.07% | 82.58% | 83.92% | 83.80% | Upgrade
|
| Operating Margin | -8.31% | -13.58% | -16.41% | -21.96% | -10.47% | -21.54% | Upgrade
|
| Profit Margin | -25.28% | -34.71% | -43.65% | -38.39% | -21.86% | -27.32% | Upgrade
|
| Free Cash Flow Margin | 24.43% | 14.11% | 24.97% | 27.49% | 27.30% | 16.59% | Upgrade
|
| EBITDA | 17.1 | 14.99 | 21.52 | 20.8 | 23.4 | 20.62 | Upgrade
|
| EBITDA Margin | 30.62% | 26.47% | 34.13% | 33.83% | 39.00% | 36.75% | Upgrade
|
| D&A For EBITDA | 21.74 | 22.67 | 31.87 | 34.29 | 29.69 | 32.71 | Upgrade
|
| EBIT | -4.64 | -7.69 | -10.35 | -13.5 | -6.28 | -12.09 | Upgrade
|
| EBIT Margin | -8.31% | -13.58% | -16.41% | -21.96% | -10.47% | -21.54% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.